Asia Spotlight: Merck In Multiple Partnerships To Finance Hep C Treatment In India
Executive Summary
Merck’s Indian arm MSD India has linked up with a financial institution and is considering national rollout of a funding plan that aims to stretch the cost of hepatitis C treatment over several months. The impact could mean that up to about 45% of the affected population might get treatment, up from 3% now.
You may also be interested in...
On Heels Of Emerging Markets Deal, Merck Ropes In India's Sun Pharma To Boost Januvia Sales
MUMBAI - In an attempt to add more teeth to its rapidly growing anti-diabetes franchise in India, Merck & Co.'s affiliate MSD India and Sun Pharmaceutical Industries Ltd. jointly announced the formation of an "India-specific strategic partnership" under which Sun will have the right to market, promote and distribute MSD's star products Januvia (sitagliptin) and Janumet (sitagliptlin/metformin) under different brand names
Indian Investors Turn Cautious On Compliance Concerns
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.
Lee Takes India Compulsory License Fight To Saxagliptin
In a bold move, little known Indian drug firm Lee Pharma has applied for a compulsory license for saxagliptin in India, contending that AstraZeneca sells the diabetes drug at an exorbitant local price and that it is not being made sufficiently available. Lee also says that the originator has not responded to calls to collaborate.